phrykt

Pacira BioSciences, Inc. (PCRX): who owns it and who trades it

As of Nov 16, 2026, PCRX insiders reported 16 open-market sales worth $2.5M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Shawn Cross (CFO), with $1.3M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Pacira BioSciences

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PCRX

251 funds and institutions reported PCRX shares worth $1.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 17.0%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.17.0%
Doma Perpetual Capital Management LLC7.1%
Vanguard Portfolio Management LLC6.1%
Dimensional Fund Advisors LP5.3%
State Street Corp5.2%
D. E. Shaw & Co., Inc.5.0%
Renaissance Technologies LLC4.4%
Vanguard Capital Management LLC4.3%
Goldman Sachs Group Inc3.9%
California State Teachers Retirement System3.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.6.71M17.04%$170M-0%
Doma Perpetual Capital Management LLC2.78M7.06%$70.5MNo change
Vanguard Portfolio Management LLC2.41M6.12%$61M-4%
Dimensional Fund Advisors LP2.10M5.35%$53.4M+2%
State Street Corp2.06M5.24%$52.3M+7%
D. E. Shaw & Co., Inc.1.95M4.96%$49.5M-2%
Renaissance Technologies LLC1.73M4.41%$44M-5%
Vanguard Capital Management LLC1.69M4.30%$42.9M-5%
Goldman Sachs Group Inc1.53M3.88%$38.7M-3%
California State Teachers Retirement System1.52M3.87%$60M+2383%
Geode Capital Management, LLC1.16M2.94%$29.4M+1%
Morgan Stanley1.14M2.91%$29M-18%
American Century Companies Inc1.02M2.59%$25.8M+22%
UBS Group AG920,2172.34%$23.3M+64%
Impax Asset Management Group plc750,0271.91%$19MNo change
Two Sigma Investments, LP724,6041.84%$18.4M+38%
Charles Schwab Investment Management Inc690,7861.76%$17.5M-6%
Sixth Street Partners Management Company, L.P.690,7861.76%$17.5M–
Gagnon Securities LLC608,6171.55%$15.4M-1%
Lsv Asset Management608,3761.55%$15.4M+18%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PCRX insiders reported $0 of open-market purchases and $2.5M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$2.5M
16 trades, 5 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Oct 8, 2026
Filed Oct 9, 2026

Purchases and sales by month

$628K$628KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 8, 2026Lauren RikerVice presidentSale plan6,000$36.32$218KForm 4
Aug 17, 2026Jonathan SloninChief Medical OfficerSale plan3,040$23.23$70.6KForm 4
Jun 11, 2026Lauren RikerVice presidentSale plan6,115$23.50$144KForm 4
Jun 4, 2026Kristen WilliamsChief Administrative OffSale plan10,259$22.27$228KForm 4
Apr 23, 2026Shawn CrossCFOSale plan12,941$25.16$326KForm 4
Apr 22, 2026Shawn CrossCFOSale plan1,500$25.01$37.5KForm 4
Apr 21, 2026Shawn CrossCFOSale plan2,845$25.01$71.2KForm 4
Apr 20, 2026Shawn CrossCFOSale plan7,714$25.14$194KForm 4
Mar 17, 2026Jonathan SloninChief Medical OfficerSale plan3,261$22.82$74.4KForm 4
Mar 17, 2026Mark FroimsonDirectorSale500$21.81$10.9KForm 4
Feb 2, 2026Lauren RikerVice presidentSale plan4,000$20.81$83.2KForm 4
Feb 2, 2026Kristen WilliamsChief Administrative OffSale plan13,137$20.53$270KForm 4
Jan 5, 2026Lauren RikerVice presidentSale plan1,416$24.24$34.3KForm 4
Dec 10, 2025Shawn CrossCFOSale plan9,104$25.14$229KForm 4
Dec 9, 2025Shawn CrossCFOSale plan15,896$25.03$398KForm 4
Nov 17, 2025Jonathan SloninChief Medical OfficerSale plan3,960$24.09$95.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Shawn CrossChief Financial Officer–$1.3MApr 23, 2026
Kristen WilliamsChief Administrative Officer–$498KJun 4, 2026
Lauren RikerSenior Vice President, Finance–$479KOct 8, 2026
Jonathan SloninChief Medical Officer–$240KAug 17, 2026
Mark FroimsonDirector–$10.9KMar 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PCRX short interest

Moderate short interest. 8.4% of PCRX shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 52%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.35M PCRX shares were sold short, 8.4% of the shares outstanding, down 21.4% from the report before. At the average daily volume of 855,601 shares, buying them all back would take about 3.9 trading days (days to cover).

Shares short, % of all shares

8.40%May 15Oct 3022.0%

Days to cover

3.9May 15Oct 3019.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.35M8.40%-21%855,6013.9
Oct 15, 20264.26M10.69%-47%3.93M1.1
Sep 30, 20268.08M20.26%+7%536,46715.1
Sep 15, 20267.56M18.97%+3%582,56413.0
Aug 31, 20267.33M18.38%+0%432,36216.9
Aug 14, 20267.30M18.31%+1%902,8178.1
Jul 31, 20267.21M18.33%+4%538,75213.4
Jul 15, 20266.96M17.70%+6%441,18415.8
Jun 30, 20266.59M16.74%+5%565,39911.7
Jun 15, 20266.28M15.95%-5%376,10816.7
May 29, 20266.60M16.76%-6%469,03614.1
May 15, 20266.99M17.76%-10%680,53410.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Pacira BioSciences company events

Pacira BioSciences filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementShared information with investors. Filing
  2. Oct 8, 2026AgreementPacira BioSciences, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Viatris Inc., a Delaware corporation, and Peach Purchaser Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent. Filing
  3. Aug 4, 2026ResultsReleased financial results. Filing
  4. Jun 30, 2026AgreementPacira BioSciences, Inc. and Pacira CryoTech, Inc., the Company’s wholly owned subsidiary, entered into a Stock and Asset Purchase Agreement with Zimmer, Inc., a subsidiary of Zimmer Biomet Holdings, Inc. Filing
  5. Jun 11, 2026LeadershipPacira BioSciences, Inc. held its 2026 Annual Meeting of Stockholders in Parsippany, New Jersey and via live webcast online at www.cesonlineservices.com/pcrx26_vm, at which the Company’s stockholders approved the Amended and Restated 2014 Employee Stock Purchase Plan. Filing
  6. Apr 30, 2026ResultsReleased financial results. Filing
  7. Feb 26, 2026ResultsReleased financial results. Filing
  8. Jan 28, 2026LeadershipThe Board of Directors of Pacira BioSciences, Inc., pursuant to the Amended and Restated Certificate of Incorporation of the Company and the Third Amended and Restated Bylaws of the Company, approved an increase of the size of the Board from nine directors to 10 directors, and appointed Dr. Samit… Filing
  9. Jan 8, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Pacira BioSciences financials

Famous investors that hold PCRX

3 of the 50 well-known investors we track reported holding PCRX in their latest 13F filing. The largest position is Jim Simons's, worth $41.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20261.67M$41.9M0.1%-4%
Ken Griffin · Citadel AdvisorsQ3 202653,708$1.3M0.0%-67%
Paul Tudor Jones · Tudor Investment CorpQ3 202613,718$344K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named PCRX in the last 120 days.

FiledHolderFormStake
Oct 30, 2026Vanguard Capital Management13G/A4.8%
Oct 30, 2026Vanguard Capital Management13G/A4.8%
Oct 13, 2026Doma Perpetual Capital Management LLC13D/A0.0%
Oct 13, 2026Doma Perpetual Capital Management LLC13D/A0.0%

Questions about Pacira BioSciences, Inc. (PCRX) stock

Who owns the most PCRX stock?

The largest reported owner of Pacira BioSciences, Inc. (PCRX) is BlackRock, Inc., with 17.0% of the company. In total, 251 funds and institutions reported holding PCRX at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are PCRX insiders buying or selling?

In the last 12 months, PCRX insiders reported no open-market purchases and 16 sales worth $2.5M. The latest trade was on Oct 8, 2026. See every trade.

What is the short interest in PCRX?

As of Oct 30, 2026, 3.35M PCRX shares were sold short, 8.4% of the shares outstanding, down 21.4% from the report before. At the average daily volume of 855,601 shares, buying them all back would take about 3.9 trading days (days to cover). See the history.

Which famous investors hold PCRX?

3 of the 50 well-known investors we track reported PCRX in their latest 13F filing, including Jim Simons, Ken Griffin, Paul Tudor Jones. The largest position is worth $41.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.